George Marinos, Francesco Torre, Shilpa Chokshi, Munther Hussain, Berwin E. Clarke, David J. Rowlands, Adrian L. W. F. Eddleston, Nikolai V. Naoumov, Roger Williams – 1 October 1995 – The T helper (Th) cell response to hepatitis B core antigen (HBcAg) was analyzed in 76 chronic hepatitis B virus (HBV) carriers with varying degrees of hepatic inflammation and HBV replication. Fifty‐five patients had active viral replication, 28 with minimal histological changes and normal alanine transaminase (ALT) and 27 with active hepatic inflammation and elevated ALT.

1 October 1995

James F. Whiting, Richard M. Green, Adam B. Rosenbluth, John L. Gollan – 1 October 1995 – Tumor necrosis factor–alpha (TNF,α), a cytokine that is produced in a variety of inflammatory diseases associated with cholestasis, is believed to be the primary mediator of the systemic effects of endotoxin. Thus, we have investigated the role of TNFα in the pathogenesis of endotoxin‐induced cholestasis in intact animals, and in the uptake of taurocholate by cultured hepatocytes.

Koert P. de Jong, Harold E. Lont, Amelie M. Bijma, Mark A. M. Brouwers, Elisabeth G. E. de Vries, Marco L. van Veen, Richard L. Marquet, Maarten J. H. Slooff, Onno T. Terpstra – 1 October 1995 – Residual tumor in the remnant liver after partial hepatectomy (PH) for colorectal liver metastases is a serious clinical problem. This fact is reflected by the high number of recurrences after potentially curative liver resections. Liver regeneration, it appears, might influence the growth of remaining micrometastases in the liver.

Wan Ping Geng, Andreas J. Schwab, Carl A. Goresky, K. Sandy Pang – 1 October 1995 – The hepatic removal of the glutathione conjugate of bromosulfophthalein (BSPGSH) was studied in the single‐pass perfused rat liver with the multiple indicator dilution (MID) technique against various background concentrations of BSPGSH (20 to 214 μmol/L) over which nonlinear binding to both plasma (albumin) and tissue proteins with two classes of binding sites was found.

Syoji Kuroki, Shuichiro Okamoto, Tokio Naito, Hitoshi Oda, Shoji Nagase, Hironori Sakai, Hajime Nawata, Hiroyuki Yamashita, Kazuo Chijiiwa, Masao Tanaka – 1 October 1995 – To examine bile acid synthesis in chronic liver diseases, serum total 7α‐hydroxycholesterol level was measured by gas‐liquid chromatography‐mass spectrometry in patients with cirrhosis (n = 23), patients with chronic hepatitis (n = 21), and control subjects (n = 18). The serum 7α‐hydroxycholesterol levels were significantly lower in patients with cirrhosis than the controls (78 ± 59 pmol/mL vs.

Joann M. Mican, Adrian M. Di Bisceglie, Tse‐Ling Fong, William D. Travis, David E. Kleiner, Bennie Baker, Dean D. Metcalfe – 1 October 1995 – Mastocytosis is a disease of mast cell hyperplasia that may involve several organ systems, including liver. Between 1988 and 1991, we conducted a retrospective‐prospective study of 41 patients with mastocytosis and found 61% had evidence of liver disease.

John F. Renz, Chris L. Mudge, Melvin B. Heyman, Steve Tomlanovich, Ralph P. Kingsford, Barbara J. Moore, John D. Snyder, Hilary A. Perr, Amie L. Paschal, John P. Roberts, Nancy L. Ascher, Jean C. Emond – 1 October 1995 – The purpose of this investigation was to assess the applicability of living‐related liver transplantation in an established regional transplant program by determining the frequency of acceptable living donors from an unselected population of pediatric transplant candidates and identify specific factors limiting application of this technique.

Michael L. Schilsky – 1 October 1995 – The process of hepatobiliary copper (Cu) secretion is still poorly understood Cu secretion as a complex with glutathione and transport via a lysosomal pathway have been proposed. The recent cloning and sequencing of the gene for Wilson disease indicates that Cu transport in liver cells may be mediated by a Cu transporting Ptype ATPase. Biochemical evidence for ATP‐dependent Cu transport in mammalian systems, however, has not been reported so far.

Carl L. Berg – 1 October 1995 – Crigler‐Najjar (CN) disease is classified into two subtypes, type I and II. The molecular basis for the difference between these types is not well understood.